Suppr超能文献

世界生物精神病学协会联盟(WFSBP)焦虑症、强迫症及创伤后应激障碍药物治疗指南——首次修订版

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

作者信息

Bandelow Borwin, Zohar Joseph, Hollander Eric, Kasper Siegfried, Möller Hans-Jürgen, Zohar Joseph, Hollander Eric, Kasper Siegfried, Möller Hans-Jürgen, Bandelow Borwin, Allgulander Christer, Ayuso-Gutierrez José, Baldwin David S, Buenvicius Robertas, Cassano Giovanni, Fineberg Naomi, Gabriels Loes, Hindmarch Ian, Kaiya Hisanobu, Klein Donald F, Lader Malcolm, Lecrubier Yves, Lépine Jean-Pierre, Liebowitz Michael R, Lopez-Ibor Juan José, Marazziti Donatella, Miguel Euripedes C, Oh Kang Seob, Preter Maurice, Rupprecht Rainer, Sato Mitsumoto, Starcevic Vladan, Stein Dan J, van Ameringen Michael, Vega Johann

机构信息

Department of Psychiatry and Psychotherapy, University of Gottingen, Gottingen, Germany.

出版信息

World J Biol Psychiatry. 2008;9(4):248-312. doi: 10.1080/15622970802465807.

Abstract

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

摘要

本报告是2002年发布指南(班德洛等人,2002年,《世界生物精神病学杂志》3:171)的更新版,介绍了焦虑症、强迫症(OCD)和创伤后应激障碍(PTSD)的药物治疗建议。自本指南第一版发布以来,已发表了大量关于抗焦虑药的新随机对照研究。特别是,现在有更多的预防复发研究表明抗焦虑药物具有持续疗效。世界生物精神病学协会联合会(WFSBP)焦虑、强迫和创伤后应激障碍药物治疗特别工作组(由30名国际专家组成的共识小组)制定的这些建议,现基于510项已发表的随机、安慰剂或对照临床试验(RCT)以及130项开放研究和病例报告。这些疾病的一线治疗药物是选择性5-羟色胺再摄取抑制剂(SSRI)、5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)和钙通道调节剂普瑞巴林。三环类抗抑郁药(TCA)对某些疾病同样有效,但许多药物的耐受性不如SSRI/SNRI。在难治性病例中,当患者没有物质滥用障碍病史时,可使用苯二氮卓类药物。本综述描述了对标准治疗无反应患者的潜在治疗选择。尽管这些指南侧重于药物治疗,但也考虑了非药物治疗。认知行为疗法(CBT)和行为疗法的其他变体在焦虑症、强迫症和创伤后应激障碍患者的对照研究中已得到充分研究,足以支持单独或与上述药物联合推荐使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验